Loading clinical trials...
Loading clinical trials...
The objective of this study is to evaluate the effect of LJPC-501 infusion on mean arterial pressure (MAP) or reduction in sum norepinephrine (NE) equivalent dosing, at Hour 2 after the start of LJPC-...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
La Jolla Pharmaceutical Company
NCT03407287 · Systemic Inflammatory Response Syndrome, Distributive Shock, and more
NCT03623529 · Catecholamine-resistant Hypotension (CRH), Distributive Shock, and more
Investigational Site
Charlotte, North Carolina
Investigational Site
Cincinnati, Ohio
Investigational Site
San Antonio, Texas
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions